June 23rd 2025
A total of 13 drugs were granted recommendation for market authorization at EMA’s CHMP June 2025 meeting.
Regulation of Biosimilars: A Matter of Variability, Similarity, and Comparability
December 2nd 2013The European Union is strengthening its pioneering role in the regulation of biosimilars by further developing the basic rules for determining the levels of compatibility for this group of drugs. There are, however, some key issues that are not easy to resolve, as evident in a recent workshop on biosimilars organized by the European Medicines Agency (EMA).
Clinical Trials Head East to Asia
December 2nd 2013The rising cost of drug development and the decreasing proportion of drug-naive population in the US and European markets are driving international pharmaceutical companies to consider emerging markets as a location to conduct their clinical trials. Asia stands out among the emerging markets given its double-digit growth rates.
Establishing a Minimum Incubation Time for Biological Indicators
The industry lacks an accepted method for establishing a minimum incubation time (MIT) of less than seven days for biological indicators (BIs). The authors propose an MIT method that provides a means for reproducible determination of BI grow-out time.
Defining and Presenting Overkill Cycle Validation
November 2nd 2013Sterilization validation must be based on a robust, quality-by-design philosophy; autoclave overkill cycles should be validated by correlating lethality data to support chosen critical process parameters, even when using overkill sterilization.